Science Explorer Interactive view Map
Company · South San Francisco · United States

Nodality (United States)

nodalityinc.comROR OpenAlex
Research works
43
▼ 92% vs 2013–17
Citations
465
10.8 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
29%
world 28%

Not ranked overall: Nodality (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.72× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 2.98× its world share, 0 worksBiochemistry, Geneti…Computer Science: 1.87× its world share, 0 worksComputer ScienceEngineering: 0.15× its world share, 0 worksEngineeringMedicine: 2.48× its world share, 1 worksMedicineBusiness, Management and Accounting: 4.22× its world share, 0 worksBusiness, Management…Social Sciences: 0.22× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Business, Management and Accounting, 4.2×. Every wedge is a field page.

Which keywords describe research at Nodality (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Prognostic Factors, Hematopoietic Stem Cells, Acute Myeloid Leukemia, AML, Gene Expression, Single-Cell, Transcriptomics and Therapeutic Targets.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Prognostic Factors11▲ 56×4 topics
  2. Hematopoietic Stem Cells6▲ 147×2 topics
  3. AML6▲ 306×1 topic
  4. Acute Myeloid Leukemia6▲ 306×1 topic
  5. Gene Expression5▲ 18×4 topics
  6. Single-Cell4▲ 479×1 topic
  7. Transcriptomics4▲ 479×1 topic
  8. Rituximab4▲ 57×2 topics
  9. Therapeutic Targets4▲ 40×2 topics
  10. Chronic Lymphocytic Leukemia4▲ 172×1 topic
  11. Genomic Aberrations4▲ 172×1 topic
  12. Cancer3▲ 4.5×7 topics
  13. Genomic Instability3▲ 49×2 topics
  14. Inflammation2▲ 2.2×9 topics
  15. Autoimmunity2▲ 19×3 topics
  16. Homologous Recombination2▲ 53×2 topics
  17. Minimal Residual Disease2▲ 53×2 topics
  18. Tumor Microenvironment2▲ 10×5 topics
  19. Cancer Genomics1▲ 57×1 topic
  20. Foxp31▲ 43×1 topic
  21. Mutational Signatures1▲ 57×1 topic
  22. TGF-ß1▲ 18×1 topic
  23. Cytokines1▲ 11×4 topics
  24. DNA Damage1▲ 23×1 topic
  25. Glycosylation1▲ 14×2 topics
  26. Immunity1▲ 8.8×4 topics
  27. Repair1▲ 61×1 topic
  28. Acute Lymphoblastic Leukemia1▲ 76×1 topic
  29. Childhood Cancer1▲ 76×1 topic
  30. Fc Receptors1▲ 27×1 topic
  31. Information Technology1▲ 8.7×2 topics
  32. Microglia1▲ 31×2 topics
  33. Neuroinflammation1▲ 9.8×2 topics
  34. Therapeutic Antibodies1▲ 21×1 topic
  35. Autoantibodies1▲ 10×2 topics
  36. High-Throughput Analysis1▲ 53×1 topic
  37. Immune Checkpoint Blockade1▲ 44×1 topic
  38. PD-1 and PD-L11▲ 44×1 topic
  39. Protein Microarrays1▲ 123×1 topic
  40. Toll-like Receptors1▲ 15×2 topics

Which research topics does Nodality (United States) publish most on?

By volume in 2022–2025: Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Acute Myeloid Leukemia Research and Recommender Systems and Techniques.

Multiple Myeloma Research and Treatments: 0 fractional worksProtein Degradation and Inhibitors: 0 fractional worksAcute Myeloid Leukemia R…0Acute Myeloid Leukemia Research: 0 fractional worksRecommender Systems and …0Recommender Systems and Techniques: 0 fractional worksDigital Innovation in In…0Digital Innovation in Industries: 0 fractional worksCorporate Governance and…0Corporate Governance and Management: 0 fractional worksPoisoning and overdose treatments: 0 fractional worksPesticide Exposure and Toxicity: 0 fractional worksMedical Case Reports and Studies: 0 fractional worksHER2/EGFR in Cancer Research: 0 fractional works
HematologyMolecular BiologyInformation SystemsManagement of Technology and Innovation5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Multiple Myeloma Research and Treatments Hematology 0 works
  2. 2 Protein Degradation and Inhibitors Molecular Biology 0 works
  3. 3 Acute Myeloid Leukemia Research Hematology 0 works
  4. 4 Recommender Systems and Techniques Information Systems 0 works
  5. 5 Digital Innovation in Industries Management of Technology and Innovation 0 works
  6. 6 Corporate Governance and Management Strategy and Management 0 works
  7. 7 Poisoning and overdose treatments Emergency Medicine 0 works
  8. 8 Pesticide Exposure and Toxicity Plant Science 0 works
  9. 9 Medical Case Reports and Studies Surgery 0 works
  10. 10 HER2/EGFR in Cancer Research Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available29.4%not open70.6%

World: 28% of research is openly available.

with international co-authors29.1%domestic only70.9%

World: 19% is written across borders.

How has Nodality (United States)'s research output changed?

Output in 2018–2022 was 92% lower than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in South San Francisco

All research institutions in South San Francisco

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.